The stock is trading at bankruptcy levels but the news being issued is that of a healthy company. The products are valuable, but sales are not good. Debt is a problem and an infusion of cash is only of value if the interim CEO can right the ship or find a strategics partner or facilitate a merger. A suitor that is a cash cow can easily move in and save a ton of money if the products are attractive. Run the numbers if it is possible on the total amount that it cost for the development of every product that the company has, including the costs to other companies and their shelf offerings and the numbers have to be staggering.
Some applicants for a position who become an immediate or eventual disappointment after being hired, looked good on paper. Former associates and employer representatives who are contacted during the hiring process usually gloss things over or hesitate to say anything potentially damaging or revealing in order to avoid any possible legal repercussions.
Anything significant or monumental would be handled in a forthright manner and not as something surprisingly added to a meeting. I think that the prior CEO was possibly incompetent and unprofessional, and I am saying this while being professional and respectful to the company current management who are not interested in focusing on the past failures with unproductive negativity. Looking at news and actions in motion, I think accounting issues need to be addressed and clarified. Concerns from common sense nuts and bolts issues to a need of a visionary outlook are being put in place. Marketing is an issue and sales representatives' morale appears to be low in some instances and there is a great need of rebuilding confidence, so that employees have an allegiance to the company and are motivated to be productive. The tone is established at the top, but there was probably neglect, to say the least. All is well now and as well as it can be considering the situation and I am hoping that success in reviving profitability is achieved as soon as is possible.
THE POINT REVIEW
News and Insights
Exelixis, Inc. Could Soar to $8.00 in a Year: Analysts
By Danial Clarke - May 25, 2016
Exelixis, Inc. (NASDAQ:EXEL) shares traded +2.50% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $7.00 within the next 52-weeks. The mean target projections are based on 3 opinions, the mean target was last revised on 05/12/16. Since analyst price targets calculations are subjective, there often can be a wide range of targets from various analysts.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have high price target of $8.00 and with a conservative view have low price target of $5.00 with a standard deviation of $1.73. Standard deviation is a measure of the dispersion of a set of data from its mean. If seeing target price from optimistic overview then it has a 30 percent upside potential from the latest closing price of $6.15. This is the consensus price target based on the analysts polled by Thomson Reuters’ First Call, the average is taken from the individual analysts which provided targets and are short term projections for the 12 months.
This is the kind of guy who knows nothing about the stock market and will be dependent upon taxpayers for food stamps in a few years if he is not already.
Pernix Therapeutics Holdings, Inc.
Focus Stock Earnings and Rating Review
by Franklin Staff
May 23, 2016
Analysts and investors will be intently looking to see if the company meets or beats earnings projections after the next report. Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) is slated to next report quarterly earnings results on or around 2016-08-04. In the last report, the company announced EPS of $-0.35 against the Zacks Research consensus estimate of $0 for the period that ended on 2016-06-30. The gap between the estimate and actual was $-0.35 which created a surprise factor of N/A%. Big surprise factors may cause substantial moves in the stock price immediately after an earnings release, or in days and weeks that follow. As the earnings report date approaches, analysts may update models based on Street sentiment and company announcements. These can be key factors pointing to whether company earnings results will hit or miss consensus projections.
Mixing in prior earnings trends, future earnings projections and company issued and projected guidance, many Street analysts will also project future price target estimates. These reports are given to institutions to help educate and guide investment analysis. These reports may also be obtained by retail investors through different platforms. At the time of writing, the consensus target on shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) stands at $6.5. This is according to 2 sell-side analysts providing data polled by Zacks Research. The analyst with the most favorable view has the stock hitting $10, while the most conservative analyst has a target projection of $3 on the stock.
Going forward the Shorts are thinking maybe I better check the medicine cabinet and inventory the personal lubricant supply.
The pattern for several trading days since the exit of the former CEO has been to Open High and Close Low. I look for stabilization to occur with a day where the stock closes unchanged or up. Hopefully today is that day.